Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma.
Long GV, Stephen Hodi F, Lipson EJ, Schadendorf D, Ascierto PA, Matamala L, Salman P, Castillo Gutiérrez E, Rutkowski P, Gogas HJ, Lao CD, Janoski De Menezes J, Dalle S, Arance A, Grob JJ, Keidel S, Shaikh A, Sobiesk AM, Dolfi S, Tawbi HA. Long GV, et al. Among authors: stephen hodi f. NEJM Evid. 2023 Apr;2(4):EVIDoa2200239. doi: 10.1056/EVIDoa2200239. Epub 2023 Mar 22. NEJM Evid. 2023. PMID: 38320023 Clinical Trial.
Health-related quality of life with nivolumab plus relatlimab versus nivolumab monotherapy in patients with previously untreated unresectable or metastatic melanoma: RELATIVITY-047 trial.
Schadendorf D, Tawbi H, Lipson EJ, Stephen Hodi F, Rutkowski P, Gogas H, Lao CD, Grob JJ, Moshyk A, Lord-Bessen J, Hamilton M, Guo S, Shi L, Keidel S, Long GV. Schadendorf D, et al. Among authors: stephen hodi f. Eur J Cancer. 2023 Jul;187:164-173. doi: 10.1016/j.ejca.2023.03.014. Epub 2023 Mar 22. Eur J Cancer. 2023. PMID: 37167764 Free article. Clinical Trial.
First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1).
Postel-Vinay S, Lam VK, Ros W, Bauer TM, Hansen AR, Cho DC, Stephen Hodi F, Schellens JHM, Litton JK, Aspeslagh S, Autio KA, Opdam FL, McKean M, Somaiah N, Champiat S, Altan M, Spreafico A, Rahma O, Paul EM, Ahlers CM, Zhou H, Struemper H, Gorman SA, Watmuff M, Yablonski KM, Yanamandra N, Chisamore MJ, Schmidt EV, Hoos A, Marabelle A, Weber JS, Heymach JV. Postel-Vinay S, et al. Among authors: stephen hodi f. J Immunother Cancer. 2023 Mar;11(3):e005301. doi: 10.1136/jitc-2022-005301. J Immunother Cancer. 2023. PMID: 36927527 Free PMC article. Clinical Trial.
Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade.
Gomez-Roca C, Cassier P, Zamarin D, Machiels JP, Perez Gracia JL, Stephen Hodi F, Taus A, Martinez Garcia M, Boni V, Eder JP, Hafez N, Sullivan R, Mcdermott D, Champiat S, Aspeslagh S, Terret C, Jegg AM, Jacob W, Cannarile MA, Ries C, Korski K, Michielin F, Christen R, Babitzki G, Watson C, Meneses-Lorente G, Weisser M, Rüttinger D, Delord JP, Marabelle A. Gomez-Roca C, et al. Among authors: stephen hodi f. J Immunother Cancer. 2022 May;10(5):e004076. doi: 10.1136/jitc-2021-004076. J Immunother Cancer. 2022. PMID: 35577503 Free PMC article. Clinical Trial.
Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors.
Rahma OE, Tyan K, Giobbie-Hurder A, Brohl AS, Bedard PL, Renouf DJ, Sharon E, Streicher H, Hathaway E, Cunningham R, Manos M, Severgnini M, Rodig S, Stephen Hodi F. Rahma OE, et al. Among authors: stephen hodi f. J Immunother Cancer. 2022 Mar;10(3):e003569. doi: 10.1136/jitc-2021-003569. J Immunother Cancer. 2022. PMID: 35264434 Free PMC article. Clinical Trial.
Soluble PD-L1 as an early marker of progressive disease on nivolumab.
Mahoney KM, Ross-Macdonald P, Yuan L, Song L, Veras E, Wind-Rotolo M, McDermott DF, Stephen Hodi F, Choueiri TK, Freeman GJ. Mahoney KM, et al. Among authors: stephen hodi f. J Immunother Cancer. 2022 Feb;10(2):e003527. doi: 10.1136/jitc-2021-003527. J Immunother Cancer. 2022. PMID: 35131863 Free PMC article.
Improved prognosis and evidence of enhanced immunogenicity in tumor and circulation of high-risk melanoma patients with unknown primary.
Tarhini AA, Lee SJ, Tan AC, El Naqa IM, Stephen Hodi F, Butterfield LH, LaFramboise WA, Storkus WJ, Karunamurthy AD, Conejo-Garcia JR, Hwu P, Streicher H, Sondak VK, Kirkwood JM. Tarhini AA, et al. Among authors: stephen hodi f. J Immunother Cancer. 2022 Jan;10(1):e004310. doi: 10.1136/jitc-2021-004310. J Immunother Cancer. 2022. PMID: 35074904 Free PMC article. Clinical Trial.
Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067.
Regan MM, Mantia CM, Werner L, Tarhini AA, Larkin J, Stephen Hodi F, Wolchok J, Postow MA, Stwalley B, Moshyk A, Ritchings C, Re S, van Dijck W, McDermott DF, Atkins MB. Regan MM, et al. Among authors: stephen hodi f. J Immunother Cancer. 2021 Nov;9(11):e003743. doi: 10.1136/jitc-2021-003743. J Immunother Cancer. 2021. PMID: 34799400 Free PMC article.
Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trial.
Ott PA, Nazzaro M, Pfaff KL, Gjini E, Felt KD, Wolff JO, Buchbinder EI, Haq R, Sullivan RJ, Lawrence DP, McDermott DF, Severgnini M, Giobbie-Hurder A, Rodig SJ, Stephen Hodi F. Ott PA, et al. Among authors: stephen hodi f. J Immunother Cancer. 2021 Nov;9(11):e003318. doi: 10.1136/jitc-2021-003318. J Immunother Cancer. 2021. PMID: 34772758 Free PMC article. Clinical Trial.
Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition.
Rogiers A, Pires da Silva I, Tentori C, Tondini CA, Grimes JM, Trager MH, Nahm S, Zubiri L, Manos M, Bowling P, Elkrief A, Papneja N, Vitale MG, Rose AAN, Borgers JSW, Roy S, Mangana J, Pimentel Muniz T, Cooksley T, Lupu J, Vaisman A, Saibil SD, Butler MO, Menzies AM, Carlino MS, Erdmann M, Berking C, Zimmer L, Schadendorf D, Pala L, Queirolo P, Posch C, Hauschild A, Dummer R, Haanen J, Blank CU, Robert C, Sullivan RJ, Ascierto PA, Miller WH Jr, Stephen Hodi F, Suijkerbuijk KPM, Reynolds KL, Rahma OE, Lorigan PC, Carvajal RD, Lo S, Mandala M, Long GV. Rogiers A, et al. Among authors: stephen hodi f. J Immunother Cancer. 2021 Jan;9(1):e001931. doi: 10.1136/jitc-2020-001931. J Immunother Cancer. 2021. PMID: 33468556 Free PMC article.
19 results